CPIX vs. NKTR, ASMB, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, and RPRX
Should you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceuticals" industry.
Cumberland Pharmaceuticals vs.
Cumberland Pharmaceuticals (NASDAQ:CPIX) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, community ranking, dividends and institutional ownership.
Cumberland Pharmaceuticals has higher earnings, but lower revenue than Nektar Therapeutics. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cumberland Pharmaceuticals has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.
Nektar Therapeutics has a consensus price target of $4.92, indicating a potential upside of 459.35%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Cumberland Pharmaceuticals.
Nektar Therapeutics received 449 more outperform votes than Cumberland Pharmaceuticals when rated by MarketBeat users. Likewise, 70.78% of users gave Nektar Therapeutics an outperform vote while only 41.69% of users gave Cumberland Pharmaceuticals an outperform vote.
15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 43.3% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 3.7% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Nektar Therapeutics had 21 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 24 mentions for Nektar Therapeutics and 3 mentions for Cumberland Pharmaceuticals. Nektar Therapeutics' average media sentiment score of 0.41 beat Cumberland Pharmaceuticals' score of 0.40 indicating that Nektar Therapeutics is being referred to more favorably in the news media.
Cumberland Pharmaceuticals has a net margin of -29.54% compared to Nektar Therapeutics' net margin of -180.70%. Cumberland Pharmaceuticals' return on equity of -9.50% beat Nektar Therapeutics' return on equity.
Summary
Nektar Therapeutics beats Cumberland Pharmaceuticals on 12 of the 19 factors compared between the two stocks.
Get Cumberland Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cumberland Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CPIX) was last updated on 3/20/2025 by MarketBeat.com Staff
